A 29-year-old man with a history of oculocutaneous albinism presented to the ED complaining of progressive dyspnea on exertion. One month prior to admission, the patient had begun to experience worsening dyspnea provoked by routine household activities. Additionally, he had developed a nonproductive cough, exacerbated by cold weather. He denied associated chest pain, hemoptysis, fever, chills, or night sweats. He denied any new exposures or sick contacts in the recent past. A review of systems was signifi cant for a history of epistaxis and frequent bruising. Born in Honduras, he had immigrated to the United States approximately 10 years prior to his presentation to our facility. Furthermore, there was no family history of albinism, bleeding disorders, or pulmonary disease.
[ Pulmonary, Critical Care, and Sleep Pearls ]
Physical Examination Findings
Physical examination revealed an albino man in no acute distress. He was afebrile, with a pulse of 72 beat/min, BP of 125/72 mm Hg, respiratory rate of 20 breaths/ min, and oxygen saturation of 90% on room air. Central cyanosis and digital clubbing were noted. Ocular examination revealed a horizontal nystagmus and red refl exes bilaterally. Cardiopulmonary auscultation was notable for Velcro-like inspiratory rales at bilateral lung bases and a prominent second heart sound. Th e remainder of his examination was unremarkable.
Diagnostic Studies
Laboratory investigation revealed a normal blood cell count and basic chemistry panel. Routine bacterial, fungal, and mycobacterial cultures of sputum were negative, as were serology testing for HIV, coccidioidomycosis, TB, and histoplasmosis. Th e admission chest radiograph is shown in Figure 1 . High-resolution CT scan of the chest was performed; representative sections are shown in Figure 2 . Echocardiography revealed a pulmonary artery systolic pressure of 90 mm Hg and right ventricular strain. Right-sided heart catheterization revealed a pulmonary artery systolic pressure of 70 mm Hg and a pulmonary capillary wedge pressure of 7 mm Hg. Pulmonary function testing showed an FVC of 28% predicted, total lung capacity of 35% predicted, and diff usion capacity of 33% predicted. Six-minute walk distance was markedly reduced; additionally, arterial oxygen saturation of 71% was noted during exercise. During further investigation, electron microscopy of the platelets showed absence of dense granules ( Fig 3 ) . HPS can manifest with various dermatologic, hematologic, and pulmonary signs and symptoms. Th e fi rst, and oft en most telling, clue in establishing the diagnosis of HPS is the dermatologic manifestation of the disease. All patients with HPS have some degree of oculocutaneous albinism, characterized by hypopigmentation of the skin, hair, and eyes, caused by a defect in the tyrosine transport system and impairment in the melanin production pathway. Ocular changes such as nystagmus, strabismus, and decreased to complete loss of visual acuity may also be observed.
What is the diagnosis?
Bleeding diathesis is the second most common presenting symptom of HPS, with the aff ected individuals experiencing easy bruising, epistaxis, and gingival bleeding. Th is is oft en attributed to platelet dysfunction caused by the lack of dense granules within the platelets. Th e third, and the most detrimental, set of presenting symptoms of HPS are those caused by pulmonary fi brosis, which are most commonly attributed to a sporadic mutation in the HPS-1 gene. Patients oft en present with insidious, yet progressive, worsening of dyspnea caused by the development of pulmonary fi brosis within the third or fourth decades of life.
Th e severity of pulmonary fi brosis in patients with HPS oft en correlates with the degree of ceroid deposition. Ceroid lipofuscin, a lipid protein complex, can deposit in numerous organs of patients with HPS. Th ese particles form residues within the lysosomes of aff ected patients and are the primary contributor to the morbidity associated with the HPS. It is hypothesized that the depo sition of these lipid-fi lled lysosomes into type 2 pneumocytes and alveolar macrophages triggers a cascade of inflammation, cytokine production, and fi broblast proliferation, ultimately culminating in the development of pulmonary fi brosis.
More recent studies have focused on lysosome-related organelles (LROs) as a cause of the signs and symptoms of certain subgroups of patients with HPS. LROs are very similar in function to lysosomes, and any disturbance in their function could lead to problems with cellular trafficking and transport. It is speculated that mutations in HPS genes could lead to defects in the LROs within melanosomes of the melanocytes, d granules of platelets, and lamellar bodies of type 2 epithelial cells of the lungs, leading to the clinical fi ndings of HPS.
High-resolution CT scanning of the chest is the modality of choice when evaluating the extent of pulmonary fi brosis in patients with HPS. In the early stages of the disease, imaging reveals septal thickening, ground-glass attenuation, and mild reticulation in the peripheral lung fi elds. With disease progression, the central portions of the lungs become increasingly involved, with moderate to severe reticulation, traction bronchiectasis, subpleural cysts, and peribronchovascular thickening. Unlike this patient, most individuals with HPS who are under the age of 30 years have only minimal amounts of pulmonary fi brosis. Electron microscopy can confi rm the diagnosis by demonstrating the absence of plateletdense bodies.
Despite the interest in the clinical consequences of pulmonary fi brosis in HPS, treatment options remain sparse. In patients with idiopathic pulmonary fi brosis, pirfenidone, an antifi brotic agent that inhibits tumor growth factor-b -mediated fi broblast proliferation and collagen synthesis, has been shown to reduce disease progression as refl ected by lung function and exercise tolerance. In a 2002 study of patients with HPS-associated pulmonary fi brosis, pirfenidone, compared with placebo, was shown to slow the rate of decline in FVC. However, in a more recent study evaluating a similar cohort of patients with HPS-associated pulmonary fi brosis, treatment with pirfenidone exhibited no signifi cant benefi t compared with placebo.
Although lung transplant is a consideration for patients with advanced pulmonary fi brosis of diverse causes, the e227 journal.publications.chestnet.org bleeding diathesis associated with HPS has been viewed as a contraindication. Because the severity of platelet dysfunction varies among patients with HPS, those patients with only mild bleeding diathesis should be considered. To our knowledge, there is at least one reported case of successful bilateral lung transplantation in a patient with HPS. In this case, the patient was supported through surgery with platelet transfusions. Desmopressin administration also temporarily corrects the platelet dysfunction associated with HPS and could be used to support select patients through major surgical procedures such as transplant. Unfortunately, lung transplant centers are rarely accessible to patients from the geographic areas where HPS is most prevalent.
Clinical Course
Th e patient was informed of his diagnosis of HPS-1-associated pulmonary fi brosis. Treatment with oxygen and pulmonary rehabilitation were initiated. Th e patient opted to return to Honduras where he was to receive regular pulmonary care.
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